Beyond sensitivity: artificial intelligence and micro‐ultrasonography in prostate cancer detection

We congratulate Zhou et al. [1] for their important study, in which the Prostate Micro-Ultrasound Network (ProMUS-NET), a U-Net-based model, achieved higher sensitivity than expert urologists on micro-ultrasonography (MUS). This represents a step toward democratising targeted biopsy in contexts where multiparametric MRI (mpMRI) remains costly or inaccessible. However, beyond demonstrating technical performance, this study prompts a re-examination of artificial intelligence's (AI's) role in prostate cancer diagnostics. We highlight three perspectives. The ProMUS-NET underperformed in detecting anterior cancers, a limitation long recognised for MUS [1, 2]. Nearly one-third of prostate cancers arise anteriorly. This invites the insight that AI should not only compensate for perceptual errors but also stimulate advances in probe design, adaptive beamforming, or physics-informed algorithms. Although sensitivity improved, false positives increased [1]. Similar trade-offs have been observed in MRI-targeted pathways [3]. Translation into practice therefore requires balancing diagnostic yield with feasibility and patient anxiety. Interfaces presenting probabilistic outputs, rather than binary calls, may enable real-time adjudication by urologists. Inter-observer inconsistency is a major limitation of MUS [1]. AI re-frames this variability: the goal may be harmonisation rather than elimination. Hybrid frameworks that combine AI segmentation with clinician judgement and MRI priors could yield systems more robust than any single modality [4]. In conclusion, Zhou et al. [1] show that AI can elevate MUS beyond current human performance. Its greater promise may lie in catalysing hardware redesign, multimodal integration, and equitable deployment. This positions AI not as a competitor but as a catalyst for sustainable, clinician-led diagnostic ecosystems. No specific funding was received for this study. The authors declare no conflicts of interest.

Authors

Institutions

Publication Details

Journal
British Journal of Urology
Published
2026-02-12
DOI
https://doi.org/10.1111/bju.70112
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Beyond sensitivity: artificial intelligence and micro‐ultrasonography in prostate cancer detection

Schawanya K. Rattanapitoon, Nathkapach K. Rattanapitoon, Patpicha Arunsan, Tirayut Veerasatian
British Journal of Urology
Prostate Cancer Diagnosis and Treatment
article

Beyond sensitivity: artificial intelligence and micro‐ultrasonography in prostate cancer detection

Schawanya K. Rattanapitoon, Nathkapach K. Rattanapitoon, Patpicha Arunsan, Tirayut Veerasatian
article en

Abstract

We congratulate Zhou et al. [1] for their important study, in which the Prostate Micro-Ultrasound Network (ProMUS-NET), a U-Net-based model, achieved higher sensitivity than expert urologists on micro-ultrasonography (MUS). This represents a step toward democratising targeted biopsy in contexts where multiparametric MRI (mpMRI) remains costly or inaccessible. However, beyond demonstrating technical performance, this study prompts a re-examination of artificial intelligence's (AI's) role in prostate cancer diagnostics. We highlight three perspectives. The ProMUS-NET underperformed in detecting anterior cancers, a limitation long recognised for MUS [1, 2]. Nearly one-third of prostate cancers arise anteriorly. This invites the insight that AI should not only compensate for perceptual errors but also stimulate advances in probe design, adaptive beamforming, or physics-informed algorithms. Although sensitivity improved, false positives increased [1]. Similar trade-offs have been observed in MRI-targeted pathways [3]. Translation into practice therefore requires balancing diagnostic yield with feasibility and patient anxiety. Interfaces presenting probabilistic outputs, rather than binary calls, may enable real-time adjudication by urologists. Inter-observer inconsistency is a major limitation of MUS [1]. AI re-frames this variability: the goal may be harmonisation rather than elimination. Hybrid frameworks that combine AI segmentation with clinician judgement and MRI priors could yield systems more robust than any single modality [4]. In conclusion, Zhou et al. [1] show that AI can elevate MUS beyond current human performance. Its greater promise may lie in catalysing hardware redesign, multimodal integration, and equitable deployment. This positions AI not as a competitor but as a catalyst for sustainable, clinician-led diagnostic ecosystems. No specific funding was received for this study. The authors declare no conflicts of interest.

British Journal of Urology
Buriram Rajabhat University (TH), Maharat Nakhon Ratchasima Hospital (TH), Nakhon Ratchasima Rajabhat University (TH), Vongchavalitkul University (TH)
Openalex Percentile: Top 60%
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.